NCT07044050
A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 10, 2025
Completion: Dec 31, 2026